Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 9/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 6/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121187 | 0.82 | DPP4 (0.44) | DPP8DPP9DPP7ADAMTS5NAMPT | |
| SCHEMBL31121184 | 0.78 | FAP (0.39) | ADAMTS5NAMPTMMP2MMP13 | |
| SCHEMBL23745411 | 0.76 | ADAMTS5 (0.62) | ADAMTS5MMP2MMP13 | |
| SCHEMBL30012633 | 0.76 | NAMPT (0.33) | NAMPTMEN1 | |
| SCHEMBL30013223 | 0.75 | ABHD6 (0.38) | NAMPT | |
| SCHEMBL30013191 | 0.70 | ADAMTS5 (0.34) | ADAMTS5MMP2MMP13 | |
| SCHEMBL3478866 | 0.69 | DPP8 (0.60) | DPP8DPP9DPP7TRAP1HSP90B1 | |
| SCHEMBL23745420 | 0.69 | ADAMTS5 (0.56) | DPP8DPP9DPP7ADAMTS5 | |
| SCHEMBL3055486 | 0.66 | TRAP1 (0.56) | DPP8DPP9DPP7TRAP1HSP90B1 | |
| SCHEMBL497487 | 0.66 | TRAP1 (0.56) | DPP8DPP9DPP7TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299360-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | DPP8 138/4885DPP9 91/4885DPP7 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.